A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Dato-DXd|DRUG: Paclitaxel|DRUG: Nab-paclitaxel|DRUG: Carboplatin|DRUG: Capecitabine|DRUG: Eribulin mesylate
Sponsor: AstraZeneca
Collaborators: Daiichi Sankyo